Methods of predicting behavior of cancers

• US 20070231828A1
• Filed: 11/07/2006
• Published: 10/04/2007
• Est. Priority Date: 10/01/2003
• Status: Abandoned Application

• Current Assignee: Johns Hopkins University
• Original Assignee: Johns Hopkins University
• Inventors: Beachy, Philip, Berman, David, Schaeffer, Edward, DeMarzo, Angelo, Karhadkar, Sunil
• Application Number:
  US11/594,281
• Publication Number:
  US 20070231828A1
• Time in Patent Office: Days
• US Class Current: 435/7.100
• CPC Class Codes: G01N 33/57434 of prostate

Abstract

Elevated Hedgehog (Hh) pathway activity, including ligand stimulated Hh pathway activity, was detected in prostate tumors, and determined to be associated with growth and proliferation of the cancer cells. Accordingly, methods are provided for treating a prostate cancer associated with elevated Hh pathway activity by reducing or inhibiting the Hh pathway activity. Also provided are methods of identifying a prostate tumor of a subject as, or as capable of becoming lethal and/or metastatic.

Claims

1. A method of diagnosing prostate cancer in a subject comprising detecting elevated levels of Hedgehog (Hh) pathway activity in cells from the subject, as compared with corresponding normal cells.

2. The method of claim 1, further comprising detecting elevated expression of at least one Hh pathway polypeptide or polynucleotide encoding the polypeptide.

3. The method of claim 2, wherein the Hh pathway polypeptide is selected from the group consisting of Smoothened, Gli1, Gli2, Gli3, Fused, Supporessor of Fused, Indian Hedgehog, Sonic Hedgehog, and Desert Hedgehog.

4. The method of claim 1, further comprising detecting elevated PTCH levels as compared with corresponding normal cells.

5. The method of claim 1, wherein the cells are from a biopsy sample obtained from the subject.

6. The method of claim 1, wherein the cells are from a bodily fluid obtained from the subject.

7. The method of claim 1, wherein the cells are prostate cells.

8. The method of claim 2, which comprises performing real-time polymerase chain reaction on the polynucleotide.

23. The method of claim 1, wherein the prostate tumor is malignant.

9. A method of identifying a subject at risk of recurrence of prostate cancer comprising detecting elevated levels of Hedgehog (Hh) pathway activity in prostate cells from the subject as compared with corresponding normal cells.

10. The method of claim 9, further comprising detecting elevated expression of at least one Hh pathway polypeptide or polynucleotide encoding the polypeptide.

11. The method of claim 10, wherein the Hh pathway polypeptide is selected from the group consisting of Smoothened, Gli1, Gli2, Gli3, Fused, Supporessor of Fused, Indian Hedgehog, Sonic Hedgehog, and Desert Hedgehog.

12. The method of claim 9, further comprising detecting elevated PTCH levels as compared with corresponding normal cells.

13. The method of claim 10, which comprises performing real-time polymerase chain reaction on the polynucleotide.

14. The method of claim 9, wherein the cells are from a biopsy sample obtained from the subject.

15. The method of claim 9, wherein the cells are from a bodily fluid obtained from the subject.

16. The method of claim 9, wherein the prostate cells are obtained from a prostatectomy specimen.

17. The method of claim 14, wherein the detecting occurs 1-15 years after prostatectomy.

18. A method of identifying a prostate tumor of a subject as, or as capable of becoming, lethal and/or metastatic, comprising detecting elevated levels of Hedgehog (Hh) pathway activity as compared with corresponding normal cells.

19. The method of claim 18, further comprising detecting elevated expression of at least one Hh pathway polypeptide or polynucleotide encoding the polypeptide.

20. The method of claim 19, wherein the Hh pathway polypeptide is selected from the group consisting of Smoothened, Gli1, Gli2, Gli3, Fused, Supporessor of Fused, Indian Hedgehog, Sonic Hedgehog, and Desert Hedgehog.

21. The method of claim 18, further comprising detecting elevated PTCH levels as compared with corresponding normal cells.

22. The method of claim 19, which comprises performing real-time polymerase chain reaction on the polynucleotide.

24. The method of claim 19, further comprising contacting the polypeptide with an antibody.

25. The method of claim 24, wherein the antibody is an anti-Hh antibody.